Beacon Biosignals Acquires Dreem, Launches At-Home Sleep Monitoring Services For Clinical Trials

Beacon Biosignals, the leading computational neurodiagnostics and electroencephalogram (EEG) analytics company, is pleased to announce that it has completed the acquisition of the research and development business of Dreem, a Paris-based pioneer in at-home sleep monitoring. This strategic acquisition signifies a remarkable milestone, setting the stage for clinical trial assessments at scale via the integration of Dreem's clinically-validated hardware with Beacon's next-generation EEG analytics platform.